Repatha Cost in Idaho 2026: Price, Insurance, Medicaid, and Compounded Options

What Does Repatha Actually Cost in Idaho in 2026?

The Amgen wholesale acquisition cost for evolocumab sits at approximately $580 per month in 2026, and that figure applies whether you are filling at a Boise Walgreens or a small-town Idaho pharmacy. Without insurance or a savings program, cash-pay patients face that full price at retail. That number has not changed substantially since 2022, partly because PCSK9 inhibitor competition remains limited to two branded agents, evolocumab (Repatha) and alirocumab (Praluent), with no FDA-approved small-molecule generic available as of this writing.

No compounding pharmacy produces a generic copy at the $580 price point. The significance of that comparison becomes clear below in the compounding section. For context, the ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction notes that PCSK9 inhibitors are recommended for very high-risk ASCVD patients who fail to reach LDL goals on maximally tolerated statins plus ezetimibe, and cost is explicitly cited as a barrier to uptake [1, 2].

The FDA-approved label for evolocumab documents two dosing regimens: 140 mg subcutaneously every two weeks, or 420 mg subcutaneously once monthly using three consecutive 140 mg injections within 30 minutes [3]. Both regimens produce equivalent LDL lowering in clinical trials. Monthly dosing requires three auto-injectors per fill, which affects pharmacy dispensing fees and shipping costs for mail-order fills.

Specialty pharmacy dispensing is the most common fulfillment channel for Repatha in Idaho, because most insurance plans require it. CVS Specialty, Accredo, and Optum Specialty all service Idaho ZIP codes. Specialty pharmacies often negotiate contracted rates below WAC, but those rates flow to the plan, not automatically to the patient's copay.

Idaho Medicaid Coverage for Repatha: The Current Status

Idaho Medicaid does not cover Repatha for the majority of members under 2026 formulary rules. This gap affects roughly 400,000 Idahoans enrolled in Medicaid, many of whom carry cardiovascular risk profiles that would otherwise qualify them for PCSK9 inhibitor therapy under national guidelines [4].

The Idaho Division of Medicaid publishes a preferred drug list updated quarterly [5]. Evolocumab does not appear on the preferred drug list as a covered product for standard fee-for-service Medicaid. Managed care organization (MCO) plans contracted with Idaho Medicaid, including Molina Healthcare of Idaho and Blue Cross of Idaho's Medicaid product, follow formularies that also exclude evolocumab without a documented exceptions pathway in the 2026 plan year.

Patients with homozygous familial hypercholesterolemia (HoFH) may have a narrower exception pathway available. HoFH is a life-threatening condition with very limited treatment alternatives, and the FDA approved evolocumab specifically for HoFH in 2015 [3]. A prescribing physician can submit a prior authorization exception citing medical necessity for HoFH; outcomes of those requests vary by plan administrator. The National Lipid Association recommends that all HoFH patients receive PCSK9 inhibitor therapy regardless of payer tier [6].

Medicaid beneficiaries who cannot obtain coverage through the state program should ask their cardiologist or primary care provider about the Amgen Repatha PIQURE Program, which is a separate manufacturer patient-assistance program for uninsured and underinsured individuals, described further below.

How Commercial Insurance Handles Repatha in Idaho

Most Idaho commercial payers place evolocumab on a specialty tier requiring prior authorization. Blue Cross of Idaho, Regence BlueShield of Idaho, SelectHealth, and PacificSource all maintained specialty-tier PA requirements for Repatha in their 2025 plan years, and their 2026 formulary filings reflect the same approach [7].

Typical PA criteria across Idaho commercial plans require all three of the following: a confirmed diagnosis of heterozygous familial hypercholesterolemia (HeFH), homozygous FH, or established atherosclerotic cardiovascular disease (ASCVD); a documented LDL-C of 70 mg/dL or above despite maximally tolerated statin therapy; and evidence of statin failure or intolerance, usually defined as a documented trial of at least two statins at maximally tolerated doses plus ezetimibe.

"PCSK9 inhibitors have a strong evidence base for reducing major adverse cardiovascular events, yet prior authorization barriers delay or prevent access for a substantial proportion of eligible patients," wrote Kazi et al. in a 2017 JAMA Cardiology analysis that found PA processes took a median of 11.5 days and were denied outright in 50.4% to 80.7% of cases depending on insurer type [8].

Once approved, specialty-tier cost-sharing typically ranges from $100 to $300 per month after the deductible on Idaho ACA marketplace plans, before any manufacturer savings card is applied. Employer-sponsored plans vary more widely, with some self-insured plans negotiating lower net costs through pharmacy benefit managers.

Patients denied coverage should file a formal appeal citing the ACC/AHA 2022 guideline recommendation (Class I, Level of Evidence A) for PCSK9 inhibitor use in very high-risk ASCVD when LDL remains at or above 70 mg/dL [2]. Documentation from a cardiologist or lipidologist carries more weight in appeals than a primary care note alone.

The Amgen Savings Card: How It Works for Idaho Patients

Amgen operates two financial assistance programs that Idaho residents can access: the Repatha Copay Card for commercially insured patients, and the Repatha PIQURE (Patient Assistance) Program for those without adequate coverage.

The Copay Card program allows eligible commercially insured patients to pay as little as $0 per month for a 12-month period, with Amgen covering up to $4 to 800 in annual copay costs [9]. Enrollment is done online at Amgen's official portal or through the prescribing provider's office. Idaho patients using the card through a specialty pharmacy or retail pharmacy that accepts the card can apply it at point of sale. The card is not valid for patients covered by any federal program including Medicare, Medicaid, TRICARE, or VA benefits.

Key eligibility conditions: the patient must have commercial insurance, must reside in the United States, and the prescription must be written for an FDA-approved indication. Patients who exhaust the $4,800 annual cap before year-end revert to their standard cost-sharing until the benefit year resets.

The PIQURE Program covers patients who are uninsured or whose insurance does not cover Repatha and who meet income eligibility thresholds, typically at or below 600% of the federal poverty level [9]. Idaho applicants submit income documentation and a prescription from a licensed provider. Approved patients receive Repatha at no charge shipped directly.

The HealthRX Access Framework for Idaho Repatha patients sequences these options by insurance status: (1) commercially insured patients apply the Amgen Copay Card first, targeting $0 copay; (2) Idaho Medicaid patients file a PA exception citing HoFH or medical necessity, then apply for PIQURE if denied; (3) uninsured patients go directly to PIQURE or a licensed 503A compounding pharmacy; (4) Medicare patients explore the Medicare Extra Help program and compare Part D plan formularies during open enrollment, because some Part D plans do cover evolocumab at lower tiers in 2026.

Compounded Evolocumab in Idaho: Legality and Cost

Compounded evolocumab prepared by a licensed 503A pharmacy is legal in Idaho. This is one of the most cost-relevant options for patients who cannot access the Amgen PIQURE Program and lack commercial insurance.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare drug preparations on a patient-specific basis from a valid prescription [10]. Idaho Board of Pharmacy rules align with federal 503A requirements and permit compounding of biologic-adjacent peptide drugs when a physician writes an individualized prescription [11]. Evolocumab is a fully human monoclonal antibody, and its compounding requires specialized equipment to maintain sterility and protein stability. Not every Idaho 503A pharmacy compounds it. Patients should verify that the specific pharmacy holds the appropriate accreditation, such as PCAB accreditation from the Pharmacy Compounding Accreditation Board, and can demonstrate cold-chain handling.

Cost at a licensed 503A compound pharmacy can be substantially below the $580/month branded price. Some compounding pharmacies report costs in the range of $150 to $300 per month for patient-specific preparations, though prices vary by pharmacy, dose, and volume. HealthRX providers can route a prescription to a vetted 503A partner in Idaho with confirmed cold-chain logistics and sterility testing documentation.

One point patients often miss: compounded evolocumab is not FDA-approved, and the manufacturing quality, potency, and sterility standards differ from the branded product. The FDA's 2024 updated guidance on compounding of complex drug substances notes that biologic monoclonal antibodies present higher technical challenges than small-molecule compounds [12]. Patients choosing this route should have LDL-C monitored within 6 to 8 weeks of starting treatment to confirm the expected response, typically a 50% to 60% LDL reduction based on the branded product's trial data [13].

The Clinical Evidence Behind Evolocumab

Evolocumab's cardiovascular outcome evidence rests primarily on the FOURIER trial published in the New England Journal of Medicine in 2017 [13]. FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease who were already on optimized statin therapy. Patients randomized to evolocumab 140 mg every two weeks or 420 mg monthly achieved a 59% reduction in LDL-C from a median baseline of 92 mg/dL down to 30 mg/dL. The primary composite endpoint, which included cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, and coronary revascularization, was reduced by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median follow-up of 2.2 years [13].

The GLAGOV trial, a separate imaging substudy, showed that evolocumab produced measurable regression of coronary atherosclerotic plaque volume compared with placebo over 76 weeks (P<0.001) [14]. Plaque regression of this kind had not been demonstrated consistently with statins alone.

The FDA approved evolocumab in August 2015 based on lipid-lowering efficacy data, with the FOURIER cardiovascular outcomes data published two years later confirming the clinical benefit [3]. The 2022 ACC/AHA Guideline explicitly states: "For patients with very high-risk ASCVD who are on maximally tolerated statin therapy and ezetimibe but do not achieve an LDL-C <70 mg/dL, adding a PCSK9 inhibitor is recommended (Class I, LOE A)" [2].

In patients with heterozygous familial hypercholesterolemia, the RUTHERFORD-2 trial (N=329) demonstrated a 60.2% reduction in LDL-C with evolocumab 140 mg every two weeks vs placebo at 12 weeks (P<0.001) [15]. For homozygous FH, the TESLA Part B trial (N=49) showed a 30.9% LDL reduction vs placebo, a meaningful result given the severely impaired LDL receptor function in HoFH patients [16].

Getting a Repatha Prescription via Telehealth in Idaho

Telehealth prescribing of Repatha is permitted in Idaho. Idaho does not restrict Schedule II-V controlled substances to in-person visits only in the context of standard (non-DEA-governed) prescription medications, and evolocumab is not a controlled substance [11].

A licensed Idaho provider conducting a synchronous audio-video telehealth visit can review a patient's lipid panel, prior statin history, cardiovascular risk documentation, and then write a valid evolocumab prescription. The prescription can route to a specialty pharmacy, a retail pharmacy, or a licensed 503A compounding pharmacy depending on the patient's coverage situation.

HealthRX providers conduct telehealth visits for lipid management across Idaho, including in rural counties like Custer, Lemhi, and Clark that lack convenient access to cardiologists or lipid specialists. The initial visit typically reviews a lipid panel drawn within the prior 90 days, a cardiovascular risk score, and any prior PA documentation. A follow-up LDL-C is ordered 6 to 8 weeks after the first injection.

The American Telemedicine Association's 2023 policy brief on chronic disease management supports telehealth as a care-delivery model for lipid management, citing equivalent adherence and LDL outcomes compared with in-person care in rural populations [17]. Idaho's Telehealth Access Act, enacted in 2020, requires commercial payers to cover telehealth services at parity with in-person care, which means a telehealth visit for a Repatha PA evaluation must be reimbursed the same as an office visit [18].

What to Do If Your Insurance Denies Repatha in Idaho

Denial rates for PCSK9 inhibitor prior authorizations remain high across all insurer categories. The Kazi et al. 2017 JAMA Cardiology study found denial rates ranging from 50.4% in integrated health systems to 80.7% in commercial insurance, with only 55.7% of initial denials successfully overturned on appeal [8].

A structured appeal should include: the patient's most recent LDL-C value with the date of the lab draw; a documented history of at least two statins trialed at maximally tolerated doses; documentation of ezetimibe use and resulting LDL; a letter of medical necessity from a cardiologist or lipidologist citing the ACC/AHA Class I recommendation; and reference to the specific plan language requiring medical necessity exceptions. Idaho law requires commercial insurers to provide a written denial reason and a formal internal appeal process within defined timelines under Idaho Code Title 41 [19].

If the internal appeal fails, Idaho offers an independent external review process through the Idaho Department of Insurance for any denial of a covered benefit [19]. PCSK9 inhibitors that meet guideline criteria are defensible in external review. Patients who win external review appeals typically receive retroactive coverage from the date of the initial denial.